Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin
Arthritis & Rheumatology · 2024-05 · 76 (5) · 783-795
DOI: 10.1002/art.42781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 15.02.2024. Verfasst von Thuong Trinh-Minh und 14 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Düsseldorf and Heinrich-Heine University, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Scleroderma, Systemic, S100 Calcium-Binding Protein A4, Skin, Fibrosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Research Foundation, Wilhelm-Sander-Foundation, Else-Kröner-Fresenius-Foundation.
Abstract (Originalsprache)
Objective
S100A4 is a DAMP protein. S100A4 is overexpressed in patients with systemic sclerosis (SSc), and levels correlate with organ involvement and disease activity. S100A4 −/− mice are protected from fibrosis. The aim of this study was to assess the antifibrotic effects of anti‐S100A4 monoclonal antibody (mAb) in murine models of SSc and in precision cut skin slices of patients with SSc.
Methods
The effects of anti‐S100A4 mAbs were evaluated in a bleomycin‐induced skin fibrosis model and in Tsk‐1 mice with a therapeutic dosing regimen. In addition, the effects of anti‐S100A4 mAbs on precision cut SSc skin slices were analyzed by RNA sequencing.
Results
Inhibition of S100A4 was effective in the treatment of pre‐established bleomycin‐induced skin fibrosis and in regression of pre‐established fibrosis with reduced dermal thickening, myofibroblast counts, and collagen accumulation. Transcriptional profiling demonstrated targeting of multiple profibrotic and proinflammatory processes relevant to the pathogenesis of SSc on targeted S100A4 inhibition in a bleomycin‐induced skin fibrosis model. Moreover, targeted S100A4 inhibition also modulated inflammation‐ and fibrosis‐relevant gene sets in precision cut SSc skin slices in an ex vivo trial approach. Selected downstream targets of S100A4, such as AMP‐activated protein kinase, calsequestrin‐1, and phosphorylated STAT3, were validated on the protein level, and STAT3 inhibition was shown to prevent the profibrotic effects of S100A4 on fibroblasts in human skin.
Conclusion
Inhibition of S100A4 confers dual targeting of inflammatory and fibrotic pathways in complementary mouse models of fibrosis and in SSc skin. These effects support the further development of anti‐S100A4 mAbs as disease‐modifying targeted therapies for SSc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospital Düsseldorf and Heinrich-Heine University, Düsseldorf, Germany.
- Charles University, Prague, Czech Republic.
- Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
- Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, and Helios St. Johannes Klinik Duisburg, Duisburg, Germany.
- Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, Germany.
- Arxx Therapeutics, Oslo, Norway, and Roskilde University, Roskilde, Denmark.
ORCID-Profile: Andrea-Hermina Györfi, Jörg H W Distler
Förderung
- German Research Foundation
- Wilhelm-Sander-Foundation
- Else-Kröner-Fresenius-Foundation
- German Federal Ministry of Education and Research (BMBF)
- MASCARA program
- Award of Medicine of the Ernst Jung Foundation
- BMBF, CompLS program
- Ministry of Health Czech Republic
Zitieren
APA
Trinh-Minh, T., Györfi, A. H., Tomcik, M., Tran-Manh, C., Zhou, X., Dickel, N., Tümerdem, B. S., Kreuter, A., Burmann, S. N., Borchert, S. V., Hussain, R. I., Hallén, J., Klingelhöfer, J., Kunz, M., & Distler, J. H. W. (2024). Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin. Arthritis & Rheumatology, 76(5), 783-795. https://doi.org/10.1002/art.42781
Vancouver
Trinh-Minh T, Györfi AH, Tomcik M, Tran-Manh C, Zhou X, Dickel N, et al. Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin. Arthritis & Rheumatology. 2024;76(5):783-795. doi:10.1002/art.42781
BibTeX
@article{TrinhMinh2024,
author = {Trinh-Minh, Thuong and Györfi, Andrea-Hermina and Tomcik, Michal and Tran-Manh, Cuong and Zhou, Xiang and Dickel, Nicholas and Tümerdem, Bilgesu Safak and Kreuter, Alexander and Burmann, Sven-Niklas and Borchert, Signe Vedel and Hussain, Rizwan Iqbal and Hallén, Jonas and Klingelhöfer, Jörg and Kunz, Meik and Distler, Jörg H W},
title = {Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin},
journal = {Arthritis & Rheumatology},
year = {2024},
volume = {76},
number = {5},
pages = {783--795},
doi = {10.1002/art.42781}
}
EUVIMED